and Circulating Tumour Cell (CTC) Analysis

Photodynamic Therapy (PDT) is a minimally invasive, localised supportive oncology approach that combines a light-sensitive drug (photosensitiser) with a specific wavelength of light to target cancer cells. The photosensitiser is administered orally, intravenously, or topically. After an uptake period of approximately 24–72 hours, the tumour is exposed to light using a laser, LED, or fibre-optic device. This activates the photosensitiser, producing reactive oxygen species that damage cancer cells while minimising effects on surrounding healthy tissue.

Circulating Tumour Cell (CTC) analysis is a non-invasive “liquid biopsy” technique that detects tumour cells that have detached from the primary tumour and entered the bloodstream. By analysing a blood sample, CTC testing provides real-time information on disease status and can help monitor treatment response and guide adjustments to supportive care strategies.

When used together, PDT and CTC analysis can complement one another as part of a comprehensive integrative oncology approach. CTC monitoring can provide ongoing information about disease progression and treatment response, while PDT offers a localised treatment option that may be incorporated into an individualised supportive care plan.